Conventional radiography and correlated factors of enthesopathies of the Achilles tendon and plantar fascia in patients with axial spondyloarthritis

Ebru Yılmaz; Özge Pasin; Loiane Cristina de Souza; Guilherme Torres Vilarino; Alexandro Andrade; Camila Gusmão Vicente de Carvalho; Barbara Bayeh; Fernando Henrique Carlos de Souza; Renata Miossi; Pleiades Tiharu Inaoka; Takashi Matsushita; Naoki Mugii; Samuel Katsuyuki Shinjo

doi:10.4081/reumatismo.2024.1709

Search

Search articles for

Advanced filters

Published AfterYearMonthDay

Published BeforeYearMonthDay

By Author

By Section

Search Results

##search.searchResults.foundPlural##

Incidence of influenza-like illness into a cohort of patients affected by chronic inflammatory rheumatism and treated with biological agents

S.L. Bello, L. Serafino, C. Bonali, N. Terlizzi, C. Fanizza, C. Anecchino, G. Lapaldula

299-306

11-12-2012

https://doi.org/10.4081/reumatismo.2012.299

2390

PDF: 1256
Drug survival and reasons for discontinuation of the first course of biological therapy in 301 juvenile idiopathic arthritis patients

M. Romano, I. Pontikaki, M. Gattinara, I. Ardoino, C. Donati, P. Boracchi, P.L. Meroni, V. Gerloni

278-285

17-03-2014

https://doi.org/10.4081/reumatismo.2013.682

2723

PDF: 1399
IgA deficiency evidence after anti-TNF-α treatment in a psoriatic arthritis patient: case report

S. Iervolino, M. Lofrano, M.N.D. Di Minno, F. Foglia, R. Scarpa, R. Peluso

40-43

19-03-2012

https://doi.org/10.4081/reumatismo.2012.40

1014

PDF: 1567
Risk of cytomegalovirus reactivation in patients with immune-mediated inflammatory diseases undergoing biologic treatment: a real matter?

J. Mencarini, M. Spinicci, F. Bartalesi

144-147

16-12-2016

https://doi.org/10.4081/reumatismo.2016.897

2019

PDF: 1162
Evaluation of Th9 lymphocytes in peripheral blood of rheumatoid arthritis patients and correlation with anti-tumor necrosis factor therapy: results from an in vitro pivotal study

R. Talotta, A. Berzi, F. Atzeni, D. Dell'Acqua, P. Sarzi Puttini, D. Trabattoni

83-89

09-09-2016

https://doi.org/10.4081/reumatismo.2016.875

1914

PDF: 951

IL RUOLO DEI LINFOCITI TH9 NELL'ARTRITE REUMATOIDE E NELLA RISPOSTA AL TRATTAMENTO CON INFLIXIMAB.: 543
GISEA: an Italian biological agents registry in rheumatology

G. Lapadula, G. Ferraccioli, C. Ferri, L. Punzi, F. Trotta

155-164

09-11-2011

https://doi.org/10.4081/reumatismo.2011.155

2405

PDF: 1615
Are biological drugs safe in pregnancy?

A. Calligaro, A. Hoxha, A. Ruffatti, L. Punzi

304-317

31-03-2015

https://doi.org/10.4081/reumatismo.2014.798

3862

PDF: 2478
Pain in rheumatic diseases: how relevant is it?

P. Sarzi-Puttini, F. Atzeni, F. Salaffi

1-3

06-06-2014

https://doi.org/10.4081/reumatismo.2014.757

2096

PDF: 1198
The impact on disability of initial treatment with methotrexate in patients with rheumatoid arthritis: results from the MARI study

M. Manara, L. Arcarese, G. Bianchi, V. Corbelli, O. Epis, R. Laurenti, A. Migliore, M. Muratore, A. Roncaglione, M. Rossini, M. Savo, L. Sinigaglia

188-194

31-12-2016

https://doi.org/10.4081/reumatismo.2016.903

1890

PDF: 964
Management of cutaneous discomfort in patients with scleroderma: a clinical trial

M. Muratore, L. Quarta, L. Raho, D. Costanza, S. Frisenda, F. Calcagnile, A. Grimaldi, E. Quarta, D. Carati, M. Guido, A. Zizza, G. Alessandrini

240-247

18-12-2013

https://doi.org/10.4081/reumatismo.2013.240

3460

PDF: 1100
A short history of anti-rheumatic therapy - VII. Biological agents

G. Pasero, P. Marson, B. Gatto

185-194

09-11-2011

https://doi.org/10.4081/reumatismo.2011.185

1554

PDF: 1254
Side effects of anti-TNFa therapy in juvenile idiopathic arthritis

Irene Pontikaki, Valeria Gerloni, Maurizio Gattinara, Alfredomaria Lurati, Alessandra Salmaso, Gabriele De Marco, Barbara Teruzzi, Elisabetta Valcamonica, Flavio Fantini

31-38

https://doi.org/10.4081/reumatismo.2006.31

1817

PDF: 2573
Successful treatment of refractory adult onset Still’s disease with rituximab

N. Belfeki, M. Smiti Khanfir, F. Said, A. Hamzaoui, T. Ben Salem, I. Ben Ghorbel, M. Lamloum, M.H. Houman

159-162

16-12-2016

https://doi.org/10.4081/reumatismo.2016.888

2552

PDF: 1275
Retention rate of tumor necrosis factor inhibitors, anti-interleukin 17, and anti-interleukin 12/23 drugs in a single-center cohort of psoriatic arthritis patients

M. Ferrito, G. Cincinelli, M. Manara, R. Di Taranto, E.G. Favalli, R. Caporali

17-07-2023

https://doi.org/10.4081/reumatismo.2023.1544

1166

PDF: 625
A short history of anti-rheumatic therapy. II. Aspirin

G. Pasero, P. Marson

148-156

https://doi.org/10.4081/reumatismo.2010.148

2505

PDF: 1556
Anti-TNFα agents in elderly patients with rheumatoid arthritis: a study of a group of 105 over sixty five years old patients

M. Filippini, C. Bazzani, S. Zingarelli, T. Ziglioli, M. Nuzzo, M. Vianelli, C. Biasini Rebaioli, R. Cattaneo, R. Gorla

41-49

https://doi.org/10.4081/reumatismo.2008.41

1186

PDF: 818
CONVENTIONAL THERAPY OF PSORIATIC ARTHRITIS: EVIDENCE-BASED REVIEW

N.J. Mchugh, E.R. Soriano

81-84

https://doi.org/10.4081/reumatismo.2007.1s.81

813

PDF: 788
Anti-tumor necrosis factor α: originators versus biosimilars, comparison in clinical response assessment in a multicenter cohort of patients with inflammatory arthropathies

C. Gioia, A. Picchianti Diamanti, R. Perricone, M.S. Chimenti, A. Afeltra, L. Navarini, A. Migliore, U. Massafra, V. Bruzzese, P. Scolieri, C. Meschini, M. Paroli, R. Caccavale, P. Scapato, R. Scrivo, F. Conti, B. Laganà, M. Di Franco

19-12-2023

https://doi.org/10.4081/reumatismo.2023.1602

1913

PDF: 469
Prophylaxis and therapy of HBV infection in 20 patients treated with disease modifying antirheumatic drugs or with biological agents for rheumatic diseases

S. Zingarelli, P. Airò, M. Frassi, C. Bazzani, M. Scarsi, M. Puoti

22-27

https://doi.org/10.4081/reumatismo.2008.22

1195

PDF: 998
On the main stages of the history of intra-articular therapy

P. Marson, G. Pasero, L. Punzi, G. Zanchin

262-268

https://doi.org/10.4081/reumatismo.2007.262

1400

PDF: 1147
The Italian Society of Rheumatology clinical practice guidelines for the management of large vessel vasculitis

N. Ughi, R. Padoan, C. Crotti, S. Sciascia, G. Carrara, A. Zanetti, D. Rozza, S. Monti, D. Camellino, F. Muratore, G. Emmi, L. Quartuccio, S. Morbelli, K. El Aoufy, S. Tonolo, R. Caporali, S. De Vita, C. Salvarani, M.A. Cimmino

07-02-2022

https://doi.org/10.4081/reumatismo.2021.1470

9494

PDF: 2125
Real-world clinical experience with secukinumab in psoriatic arthritis: an observational study and a literature review

Eleonora Celletti, Giulio Gualdi, Emanuela Sabatini, Francesco Cipollone, Fabio Lobefaro, Paolo Amerio

27-01-2025

https://doi.org/10.4081/reumatismo.2025.1694

2011

PDF: 164
Biological therapy with TNF-inhibitors in pediatric rheumatology. Review of the litterature and personal experience

V. Gerloni, I. Pontikaki, M Gattinara, F. Fantini

244-261

https://doi.org/10.4081/reumatismo.2007.244

1333

PDF: 1145
Infections in patients with rheumatoid arthritis receiving anti-cytokine therapy: biological mechanisms and clinical aspects

C. Botsios, P. Ostuni, P. Sfriso, A. Furlan, U. Fiocco, D. Sgarabotto, S. Todesco

224-235

https://doi.org/10.4081/reumatismo.2003.224

1160

PDF: 2604
COVID-19 pandemic and biological therapy in rheumatologic disorders: how to deal with?

Z. Ahmadinejad, R. Assari, N. Ayoobi Yazdi, S.-H. Mazloomi, P. Javanshayani, H. Khalili Afousi, V. Ziaee

173-177

19-11-2020

https://doi.org/10.4081/reumatismo.2020.1289

1712

PDF: 1031
Safety of anti-TNFa biological drugs

F. Trotta, G. Valentini

34-39

https://doi.org/10.4081/reumatismo.2005.4s.34

1189

PDF: 1209
Retention rate and predictor factors of drug discontinuation in axial spondyloarthritis: a focus on certolizumab and secukinumab

Ebru Atalar, Hatice Ecem Konak, Pınar Akyüz Dağlı, Bahar Özdemir Ulusoy, Özlem Karakaş, Kevser Orhan, Rezan Koçak Ulucaköy, Esra Kayacan Erdoğan, Serdar Can Güven, Orhan Küçükşahin, İsmail Doğan, Hakan Babaoğlu, Yüksel Maraş, Şükran Erten, Ahmet Omma, Berkan Armağan

26-06-2025

https://doi.org/10.4081/reumatismo.2025.1792

1574

PDF: 36
Retention rate of abatacept in rheumatoid arthritis patients in a real-life setting: results from a monocentric cohort

E. Molteni, C. Pirone, F. Ceccarelli, C. Castellani, C. Alessandri, M. Di Franco, V. Riccieri, F.R. Spinelli, R. Priori, R. Scrivo, F. Conti

24-06-2024

https://doi.org/10.4081/reumatismo.2024.1608

1665

PDF: 585
Reconstructing the pyramid as a therapeutic approach to rheumatoid arthritis

G. Ferraccioli

46-50

https://doi.org/10.4081/reumatismo.2004.1s.46

718

PDF: 707

1 - 29 of 29 items

Search

Search Results

Incidence of influenza-like illness into a cohort of patients affected by chronic inflammatory rheumatism and treated with biological agents

Drug survival and reasons for discontinuation of the first course of biological therapy in 301 juvenile idiopathic arthritis patients

IgA deficiency evidence after anti-TNF-α treatment in a psoriatic arthritis patient: case report

Risk of cytomegalovirus reactivation in patients with immune-mediated inflammatory diseases undergoing biologic treatment: a real matter?

Evaluation of Th9 lymphocytes in peripheral blood of rheumatoid arthritis patients and correlation with anti-tumor necrosis factor therapy: results from an in vitro pivotal study

GISEA: an Italian biological agents registry in rheumatology

Are biological drugs safe in pregnancy?

Pain in rheumatic diseases: how relevant is it?

The impact on disability of initial treatment with methotrexate in patients with rheumatoid arthritis: results from the MARI study

Management of cutaneous discomfort in patients with scleroderma: a clinical trial

A short history of anti-rheumatic therapy - VII. Biological agents

Side effects of anti-TNFa therapy in juvenile idiopathic arthritis

Successful treatment of refractory adult onset Still’s disease with rituximab

Retention rate of tumor necrosis factor inhibitors, anti-interleukin 17, and anti-interleukin 12/23 drugs in a single-center cohort of psoriatic arthritis patients

A short history of anti-rheumatic therapy. II. Aspirin

Anti-TNFα agents in elderly patients with rheumatoid arthritis: a study of a group of 105 over sixty five years old patients

CONVENTIONAL THERAPY OF PSORIATIC ARTHRITIS: EVIDENCE-BASED REVIEW

Anti-tumor necrosis factor α: originators versus biosimilars, comparison in clinical response assessment in a multicenter cohort of patients with inflammatory arthropathies

Prophylaxis and therapy of HBV infection in 20 patients treated with disease modifying antirheumatic drugs or with biological agents for rheumatic diseases

On the main stages of the history of intra-articular therapy

The Italian Society of Rheumatology clinical practice guidelines for the management of large vessel vasculitis

Real-world clinical experience with secukinumab in psoriatic arthritis: an observational study and a literature review

Biological therapy with TNF-inhibitors in pediatric rheumatology. Review of the litterature and personal experience

Infections in patients with rheumatoid arthritis receiving anti-cytokine therapy: biological mechanisms and clinical aspects

COVID-19 pandemic and biological therapy in rheumatologic disorders: how to deal with?

Safety of anti-TNFa biological drugs

Retention rate and predictor factors of drug discontinuation in axial spondyloarthritis: a focus on certolizumab and secukinumab

Retention rate of abatacept in rheumatoid arthritis patients in a real-life setting: results from a monocentric cohort

Reconstructing the pyramid as a therapeutic approach to rheumatoid arthritis

authors

reviewers

Categories

indexing

Keywords